Sorrento to apply antibody library technology for rIVIG production

STI president and chief executive officer Henry Ji said, "With the acquisition of the proprietary rights to the rIVIG technology, we now have access to a multi-billion dollar market opportunity applying our G-MAB antibody libraries to address unmet medical needs."

Benefits of using STI’s G-MAB library technology in rIVIG production include reduced batch-to-batch inconsistencies and production costs, minimal risk of contamination, improved potency.

The application does not require continuous human blood donor supply, according to the company.

The rIVIG technology co-inventor Dr. Tien Lee said, "Partnering our rIVIG invention with STI’s unique G-MAB technology may produce novel and highly differentiated IVIG products."

IVIG is used in the treatment of a range of medical conditions such as primary and secondary immunological deficiencies, autoimmune diseases, and acute infections and is being studied for use in treatment of Alzheimer’s disease and other neurological conditions.